8 results on '"Murakami, Takaaki"'
Search Results
2. Disruption of insulin receptor substrate 2 (IRS2) causes non-obese type 2 diabetes with β-cell dysfunction in the golden (Syrian) hamster.
- Author
-
Hirose, Michiko, Inoue, Kimiko, Matoba, Shogo, Tatebe, Takaki, Tokita, Syun, Dodo, Yukiko, Tomishima, Toshiko, Hasegawa, Ayumi, Honda, Arata, Ozaki, Mao, Shinogi, Akiko, Yanagisawa, Ryoko, Fauzi, Muhammad, Murakami, Takaaki, Inagaki, Nobuya, Tamura, Masaru, and Ogura, Atsuo
- Subjects
TYPE 2 diabetes ,GENE knockout ,GLUCOSE metabolism ,HAMSTERS ,METABOLIC models - Abstract
Because of the advent of genome-editing technology, gene knockout (KO) hamsters have become attractive research models for diverse diseases in humans. This study established a new KO model of diabetes by disrupting the insulin receptor substrate-2 (Irs2) gene in the golden (Syrian) hamster. Homozygous KO animals were born alive but with delayed postnatal growth until adulthood. They showed hyperglycemia, high HbA1c, and impaired glucose tolerance. However, they normally responded to insulin stimulation, unlike Irs2 KO mice, an obese type 2 diabetes (T2D) model. Consistent with this, Irs2 KO hamsters did not increase serum insulin levels upon glucose administration and showed β-cell hypoplasia in their pancreas. Thus, our Irs2 KO hamster provide a unique T2D animal model that is distinct from the obese T2D models. This model may contribute to a better understanding of the pathophysiology of human non-obese T2D with β-cell dysfunction, the most common type of T2D in East Asian countries, including Japan. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Stabilization of kidney function and reduction in heart failure events with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis and meta‐regression analysis.
- Author
-
Keidai, Yamato, Yoshiji, Satoshi, Hasebe, Masashi, Minamino, Hiroto, Murakami, Takaaki, Tanaka, Daisuke, Fujita, Yoshihito, and Inagaki, Nobuya
- Subjects
SODIUM-glucose cotransporters ,KIDNEY physiology ,HEART failure ,SYSTOLIC blood pressure ,SODIUM-glucose cotransporter 2 inhibitors ,TYPE 2 diabetes - Abstract
Aims: Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF) events regardless of diabetes status. However, factors associated with their efficacy in HF reduction remain unknown. This study aims to identify clinically relevant markers for the efficacy of SGLT2 inhibitors in HF risk reduction. Materials and methods: We searched PubMed/MEDLINE and EMBASE for randomized placebo‐controlled trials of SGLT2 inhibitors reporting a composite of HF hospitalization or cardiovascular death in participants with or without type 2 diabetes published until 28 February 2023. Random‐effects meta‐analysis and mixed‐effects meta‐regression were conducted to evaluate the association between the outcomes and clinical variables, including changes in glycated haemoglobin, body weight, systolic blood pressure, haematocrit and overall/chronic estimated glomerular filtration rate (eGFR) slope. Results: Thirteen trials with 90 413 participants were included. SGLT2 inhibitors reduced the hazard ratio of the composite of HF hospitalization or cardiovascular death (hazard ratio 0.77; 95% confidence interval, 0.74‐0.81; p <.0001). In meta‐regression analysis, chronic eGFR slope (eGFR change after the initial dip) was significantly associated with the composite outcome (p =.017), and each 1 ml/min/1.73 m2/year improvement in chronic eGFR slope led to a 14% reduction in the composite outcome. By contrast, changes in the other parameters showed no significant associations. Conclusions: Improvement in chronic eGFR slope, which reflects the stabilization of kidney function, is significantly associated with the efficacy of the SGLT2 inhibitor in HF, highlighting the cardiorenal axis role in the beneficial effects on HF. The chronic eGFR slope can be a surrogate marker of the effects of SGLT2 inhibitors on HF reduction. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls.
- Author
-
Kato, Tomoko, Murakami, Takaaki, Yabe, Daisuke, and Harada, Norio
- Subjects
- *
HEART failure , *ANGIOTENSINS , *HEALTH services administration , *TYPE 2 diabetes , *DIABETES - Abstract
Neprilysin inhibition might similarly block degradation of C-peptides in the kidney and thus increase the urinary C-peptide level. gl In conclusion, ARNI is in wide use for treatment of HF and hypertension, both of which are frequently observed in individuals with diabetes. As urine C-peptide levels are substantially elevated in comparison with serum C-peptide levels, the effect of sacubitril/valsartan on urine C-peptide levels would be independent of GLP-1-mediated enhancement of insulin secretion. Keywords: Angiotensin receptor-neprilysin inhibitor; C-peptide; Neprilysin EN Angiotensin receptor-neprilysin inhibitor C-peptide Neprilysin 1038 1040 3 08/25/23 20230901 NES 230901 The possible mechanism of increased urinary C-peptide due to neprilysin inhibitors is investigated. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
5. Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic β Cells.
- Author
-
Murakami, Takaaki, Inagaki, Nobuya, and Kondoh, Hiroshi
- Subjects
CELLULAR aging ,INSULIN ,TYPE 1 diabetes ,TYPE 2 diabetes ,DIABETES ,ADIPOSE tissues - Abstract
Increased insulin resistance and impaired insulin secretion are significant characteristics manifested by patients with type 2 diabetes mellitus (T2DM). The degree and extent of these two features in T2DM vary among races and individuals. Insulin resistance is accelerated by obesity and is accompanied by accumulation of dysfunctional adipose tissues. In addition, dysfunction of pancreatic β-cells impairs insulin secretion. T2DM is significantly affected by aging, as the β-cell mass diminishes with age. Moreover, both obesity and hyperglycemia-related metabolic changes in developing diabetes are associated with accumulation of senescent cells in multiple organs, that is, organismal aging. Cellular senescence is defined as a state of irreversible cell cycle arrest with concomitant functional decline. It is caused by telomere shortening or senescence-inducing stress. Senescent cells secrete proinflammatory cytokines and chemokines, which is designated as the senescence-associated secretory phenotype (SASP), and this has a negative impact on adipose tissues and pancreatic β-cells. Recent advances in aging research have suggested that senolysis, the removal of senescent cells, can be a promising therapeutic approach to prevent or improve aging-related diseases, including diabetes. The attenuation of a SASP may be beneficial, although the pathophysiological involvement of cellular senescence in diabetes is not fully understood. In the clinical application of senotherapy, tissue-context-dependent senescent cells are increasingly being recognized as an issue to be solved. Recent studies have observed highly heterogenic and complex senescent cell populations that serve distinct roles among tissues, various stages of disease, and different ages. For example, in high-fat-diet induced diabetes with obesity, mouse adipose tissues display accumulation of p21
Cip1 -highly-expressing (p21high ) cells in the early stage, followed by increases in both p21high and p16INK4a -highly-expressing (p16high ) cells in the late stage. Interestingly, elimination of p21high cells in visceral adipose tissue can prevent or improve insulin resistance in mice with obesity, while p16high cell clearance is less effective in alleviating insulin resistance. Importantly, in immune-deficient mice transplanted with fat from obese patients, dasatinib plus quercetin, a senolytic cocktail that reduces the number of both p21high and p16high cells, improves both glucose tolerance and insulin resistance. On the other hand, in pancreatic β cells, p16high cells become increasingly predominant with age and development of diabetes. Consistently, elimination of p16high cells in mice improves both glucose tolerance and glucose-induced insulin secretion. Moreover, a senolytic compound, the anti-Bcl-2 inhibitor ABT263 reduces p16INK4a expression in islets and restores glucose tolerance in mice when combined with insulin receptor antagonist S961 treatment. In addition, efficacy of senotherapy in targeting mouse pancreatic β cells has been validated not only in T2DM, but also in type 1 diabetes mellitus. Indeed, in non-obese diabetic mice, treatment with anti-Bcl-2 inhibitors, such as ABT199, eliminates senescent pancreatic β cells, resulting in prevention of diabetes mellitus. These findings clearly indicate that features of diabetes are partly determined by which or where senescent cells reside in vivo , as adipose tissues and pancreatic β cells are responsible for insulin resistance and insulin secretion, respectively. In this review, we summarize recent advances in understanding cellular senescence in adipose tissues and pancreatic β cells in diabetes. We review the different potential molecular targets and distinctive senotherapeutic strategies in adipose tissues and pancreatic β cells. We propose the novel concept of a dual-target tailored approach in senotherapy against diabetes. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
6. Non-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond.
- Author
-
Murakami, Takaaki, Fujimoto, Hiroyuki, and Inagaki, Nobuya
- Subjects
SINGLE-photon emission computed tomography ,TYPE 2 diabetes ,TYPE 1 diabetes ,POSITRON emission tomography ,GLUCAGON-like peptide-1 receptor ,GLUCAGON-like peptides ,SPIN labels - Abstract
Pancreatic beta (β)-cell dysfunction and reduced mass play a central role in the development and progression of diabetes mellitus. Conventional histological β-cell mass (BCM) analysis is invasive and limited to cross-sectional observations in a restricted sampling area. However, the non-invasive evaluation of BCM remains elusive, and practical in vivo and clinical techniques for β-cell-specific imaging are yet to be established. The lack of such techniques hampers a deeper understanding of the pathophysiological role of BCM in diabetes, the implementation of personalized BCM-based diabetes management, and the development of antidiabetic therapies targeting BCM preservation and restoration. Nuclear medical techniques have recently triggered a major leap in this field. In particular, radioisotope-labeled probes using exendin peptides that include glucagon-like peptide-1 receptor (GLP-1R) agonist and antagonist have been employed in positron emission tomography and single-photon emission computed tomography. These probes have demonstrated high specificity to β cells and provide clear images accurately showing uptake in the pancreas and transplanted islets in preclinical in vivo and clinical studies. One of these probes,
111 indium-labeled exendin-4 derivative ([Lys12 (111 In-BnDTPA-Ahx)]exendin-4), has captured the longitudinal changes in BCM during the development and progression of diabetes and under antidiabetic therapies in various mouse models of type 1 and type 2 diabetes mellitus. GLP-1R-targeted imaging is therefore a promising tool for non-invasive BCM evaluation. This review focuses on recent advances in non-invasive in vivo β-cell imaging for BCM evaluation in the field of diabetes; in particular, the exendin-based GLP-1R-targeted nuclear medicine techniques. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
7. Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects.
- Author
-
Murakami, Takaaki, Fujimoto, Hiroyuki, Fujita, Naotaka, Hamamatsu, Keita, Yabe, Daisuke, and Inagaki, Nobuya
- Subjects
- *
GLUCAGON-like peptide-1 receptor , *GLUCAGON-like peptide-1 agonists , *GLUCOSE tolerance tests , *TYPE 2 diabetes , *BLOOD sugar - Abstract
Aims/Introduction: Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are used for treatment of type 2 diabetes mellitus worldwide. However, some patients do not respond well to the therapy, and caution must be taken for certain patients, including those with reduced insulin secretory capacity. Thus, it is clinically important to predict the efficacy of GLP‐1RA therapy. GLP‐1R‐targeted imaging has recently emerged to visualize and quantify β‐cells. We investigated whether GLP‐1R‐targeted imaging can predict the efficacy of GLP‐1RA treatment. Materials and Methods: We developed 111Indium‐labeled exendin‐4 derivative (111In‐Ex4) as a GLP‐1R‐targeting probe. Diabetic mice were selected from NONcNZO10/LtJ male mice that were fed for different durations with 11% fat chow. After 3‐week administration of dulaglutide as GLP‐1RA therapy, mice with non‐fasting blood glucose levels <300 mg/dL and >300 mg/dL were defined as responders and non‐responders, respectively. In addition, ex vivo111In‐Ex4 pancreatic accumulations (111In‐Ex4 pancreatic values) were examined. Results: The non‐fasting blood glucose levels after treatment were 172.5 ± 42.4 mg/dL in responders (n = 4) and 330.8 ± 20.7 mg/dL in non‐responders (n = 5), respectively. Ex vivo111In‐Ex4 pancreatic values showed significant correlations with post‐treatment glycohemoglobin and glucose area under curve during an oral glucose tolerance test (R2 = 0.76 and 0.80; P < 0.01 and <0.01, respectively). The receiver operating characteristic area under curve for identifying responders by ex vivo111In‐Ex4 pancreatic values was 1.00 (P < 0.01). Conclusion: Ex vivo111In‐Ex4 pancreatic values reflected dulaglutide efficacy, suggesting clinical possibilities for expanding GLP‐1R‐targeted imaging applications. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology.
- Author
-
Murakami, Takaaki, Yabe, Daisuke, and Inagaki, Nobuya
- Subjects
- *
BULLOUS pemphigoid , *MEDICAL personnel , *CD26 antigen , *HLA histocompatibility antigens , *TYPE 2 diabetes - Abstract
It is strongly suggested that dipeptidyl peptidase-4 inhibitors are associated with increased risk of bullous pemphigoid onset, especially in the elderly. Furthermore, Kawaguchi I et al i . also showed a higher prevalence of BP in over 9,000 patients receiving DPP-4 inhibitors compared with that in the general population (DPP-4 inhibitors vs reported spontaneous incident rate: 0.0859% vs 0.0021-0.0066%)[6]. In contrast, some studies have argued that discontinuing DPP-4 inhibitors should not be considered essential, as no exacerbation of BP was observed in certain cases in which DPP-4 inhibitors were continued after BP onset[6]. [Extracted from the article]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.